Real-World Safety and Retention of Tofacitinib in Elderly Versus Non-elderly Patients With Rheumatoid Arthritis: A Retrospective Cohort Study in Taiwan
Int J Rheum Dis. 2026 May;29(5):e70683. doi: 10.1111/1756-185x.70683.ABSTRACTOBJECTIVES: Tofacitinib, the first approved oral small-molecule Janus kinase inhibitor (JAKi), is widely used for treating rheumatoid arthritis (RA). This study aims to compare the drug retention rates of tofacitinib betwee

